ArticleAmerican journal of translational research2026
Predictive value of liver fibrosis markers and model for end-stage liver disease score in evaluating the degree of esophageal and gastric varices in cirrhosis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to investigate the predictive value of liver fibrosis (LF) markers and the Model for End-Stage Liver Disease (MELD) score in assessing the severity of esophageal and gastric varices (EGV) in patients with liver cirrhosis (LC).
methodsThis retrospective study included 136 LC patients categorized by EGV severity into no EGV, mild EGV, moderate EGV, and severe EGV groups. Ordered multinomial logistic regression was used to identify independent risk factors, and multinomial ROC curves assessed the diagnostic performance of individual markers and combined models.
resultsHyaluronic acid (HA, r=0.867), laminin (LN, r=0.892), type IV collagen (CIV, r=0.885), type III procollagen N-terminal peptide (PIIINP, r=0.879), liver fibrosis 4 factor index (FIB-4, r=0.793), and MELD score (r=0.825) showed strong positive correlations with EGV severity (all
conclusionThe combined use of liver fibrosis markers and MELD score enables precise assessment of EGV severity in LC patients, providing a reliable non-invasive evaluation tool for clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.